Active	Status	Sponsor type	Region	Phase	Filter
6 Active 0 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Brenner, Ronald
NCT05729373: A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder	Recruiting	2/3	434	Europe, Japan, US	SEP-363856, Placebo	Otsuka Pharmaceutical Development & Commercialization, Inc.	Generalized Anxiety Disorder	02/26	02/26
Rosenberg, Leon
NCT05169710 / 2021-002126-24: A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.	Terminated	3	83	Europe, Canada, Japan, US	SEP-4199 CR 200 mg, SEP-4199 CR 400 mg, Placebo	Sumitomo Pharma America, Inc., Sunovion Pharmaceuticals Inc.	Depressive Episodes, Bipolar I Depression	10/23	10/23
NCT05729373: A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder	Recruiting	2/3	434	Europe, Japan, US	SEP-363856, Placebo	Otsuka Pharmaceutical Development & Commercialization, Inc.	Generalized Anxiety Disorder	02/26	02/26
CL07-ORY-2001, NCT04932291 / 2020-003469-20: Study to Test the Efficacy and Safety of Vafidemstat in Adult Borderline Personality Disorder Population	Completed	2	210	Europe, US, RoW	vafidemstat, ORY-2001, Placebo	Oryzon Genomics S.A.	Borderline Personality Disorder	10/23	11/23
Careri, Jason
NCT05624268: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD	Recruiting	3	255	US	Psilocybin, COMP360	COMPASS Pathways	Treatment Resistant Depression	02/25	02/26
NCT05729373: A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder	Recruiting	2/3	434	Europe, Japan, US	SEP-363856, Placebo	Otsuka Pharmaceutical Development & Commercialization, Inc.	Generalized Anxiety Disorder	02/26	02/26